AngioDynamics (Nasdaq:ANGO) shares are up today on second-quarter results that topped the consensus forecast. Shares of ANGO were up more than 11% at $15.24 apiece by the late morning. MassDevice‘s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — was up more than 7%. The Latham, New York–based peripheral […]
AngioDynamics
AngioDynamics slides on Q1 misses
AngioDynamics (Nasdaq:ANGO) shares took a hit today on first-quarter results that came up shy of the consensus forecast. Shares of ANGO dipped 12.6% at $18.84 apiece as the market opened today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — was up 0.5%. The Latham, N.Y.–based peripheral artery […]
AngioDynamics rises on Q3 EPS beat
AngioDynamics (Nasdaq:ANGO) shares ticked up today on third-quarter results that were mixed compared to the consensus forecast. The Latham, N.Y.-based peripheral artery disease (PAD) treatment developer posted losses of nearly $5 million, or 13¢ per share, on sales of $74 million for the three months ended Feb. 28, 2022, for a 40% bottom-line slide on […]
AngioDynamics slides on mixed bag Q2
AngioDynamics (NSDQ:ANGO) shares took a hit today on second-quarter results that were mixed compared to the consensus forecast. The Latham, N.Y.-based peripheral artery disease (PAD) treatment developer posted losses of $8.4 million, or 21¢ per share, on sales of $78.3 million for the three months ended Nov. 30, 2021, nearly doubling its losses from the […]
AngioDynamics rises on Street-beating Q4 revenues
AngioDynamics (NSDQ:ANGO) shares ticked up this morning on fourth-quarter results that beat the consensus revenue forecast. The Latham, N.Y.-based peripheral artery disease (PAD) treatment developer posted losses of -$19.5 million, or -51¢ per share, on sales of $76.8 million for the three months ended May 31, 2021, for an 87.6% bottom-line gain on sales growth […]
AngioDynamics jumps on Street-beating Q1
AngioDynamics (NSDQ:ANGO) shares skyrocketed today on first-quarter results that topped the consensus forecast. Shares of ANGO were up 13.2% at $12.01 per share in mid-morning trading today. The Latham, N.Y.-based peripheral artery disease (PAD) treatment developer posted losses of -$4.3 million, or -11¢ per share, on sales of $70.2 million for the three months ended Aug. […]
Angiodynamics launches atherectomy system
AngioDynamics (NSDQ:ANGO) announced today that it launched the Auryon atherectomy system for treating peripheral artery disease (PAD). Latham, N.Y.-based AngioDynamics’ newly developed, FDA-cleared Auryon atherectomy system uses lasers to treat PAD lesions and occlusions, both above and below the knee in any type or length with minimal impact on the vessel walls, according to a news […]
AngioDynamics lands 510(k) for ‘smart’ implantable port
AngioDynamics (NSDQ:ANGO) announced today that it received FDA 510(k) clearance and CE Mark approval for its SmartPort+ implantable port product. SmartPort+ is an implantable, subcutaneous port for those who require long-term access to the central venous system for blood specimen withdrawal and administration of fluids, according to a news release. Latham, N.Y.-based AngioDynamics’ device utilizes the […]
MedTech 100 roundup: Industry hits pandemic peak
After five months since medtech stocks peaked before the COVID-19 pandemic rocked the markets, the industry inched back toward that pre-pandemic high. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — sat at 88.9 points at the end of last week (July 17). That total represents just a -3.7% […]
AngioDynamics slides on missed Q4 revenues
AngioDynamics (NSDQ:ANGO) posted fourth-quarter results that missed the consensus forecast on Wall Street. The company reported losses of -$156.1 million, or -$4.10 per share, on sales of $58.3 million for the three months ended May 31, for a sales loss of -18.1% compared with Q4 2019. Adjusted to exclude one-time items, earnings per share were -6¢, […]
AngioDynamics takes ‘interim’ out of CFO Trowbridge’s title
AngioDynamics (NSDQ:ANGO) announced that it removed the interim label from CFO Stephen Trowbridge’s title, making him the company’s permanent CFO while appointing him to the role of executive VP. Trowbridge had served as interim CFO since Oct. 22, 2019, and was officially placed in the role on Feb. 5, 2020. He also served as a senior […]
